SEC Comment Letter 0000000000-22-013721 to BioCardia, Inc. (BCDA)
BioCardia, Inc.
Date: Dec. 20, 2022 · CIK: 0000925741 · Accession: 0000000000-22-013721
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-268862
Letter
United States securities and exchange commission logo December 20, 2022 Peter Altman President and Chief Executive Officer BioCardia, Inc. 320 Soquel Way Sunnyvale, CA 94085 Re:BioCardia, Inc. Registration Statement on Form S-3 Filed December 19, 2022 File No. 333-268862 Dear Peter Altman: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jason Drory at 202-551-8342 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Austin March
Show Raw Text
United States securities and exchange commission logo
December 20, 2022
Peter Altman
President and Chief Executive Officer
BioCardia, Inc.
320 Soquel Way
Sunnyvale, CA 94085
Re:BioCardia, Inc.
Registration Statement on Form S-3
Filed December 19, 2022
File No. 333-268862
Dear Peter Altman:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jason Drory at 202-551-8342 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Austin March